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I. INTRODUCTION 
 
Patents are as much a part of business as a handshake or playing 
eighteen holes on a warm summer morning.  They protect our ideas 
and give us protection while we desperately try to cultivate the fruits 
of our labor.  They give innovators a fighting chance in a land of 
capitalistic juggernauts, and provide enough hope to encourage the 
little guy to pursue his dreams, to invent something new, or to make 
something else better.  However, unlimited protection would be 
impractical and imprudent.  Without a proper catalyst, some 
inventions are bound to fall short of their potential.  Thus, a delicate 
balance must be struck in order to encourage innovators to continue 
doing what they do best while allowing, at the proper moment, those 
with the resources to take those innovations to the market to share 
with the rest of the world.  The balance between profit and 
innovation must remain intact. 
Over the years, the area of what is patentable has broadened 
considerably.  Patents were originally given exclusively to protect 
tangible inventions.  A person could not replicate a particular 
patented good without the permission of the patent holder.  But, 
patents have proven to be adaptable and have changed along with the 
times.  Advances in technology called for protection of intangible 
goods – protection of ideas or processes, methods of doing things 
better than the old way.1  One thing had always remained the same:  
Patents were not to be granted on discoveries.   
                                                            
* J.D. Candidate, Pepperdine University School of Law, 2016; B.S. in 
Chemistry, 2011, Ball State University. I would like to thank my family and friends 
for their support throughout law school and the members of this journal for their 
dedication in publishing this Comment. 
1 “As one academic has noted: 'IP is now implicated in routine, creative, 
communicative, and just plain consumptive acts that each of us perform everyday. 
The reach of the rights has been expanded just at the same moment that their 
practical effect has been transformed.” Genomics, and the Patenting of DNA: 
Review of potential implications for health in developing countries, WORLD 
HEALTH ORG. 11 (2005), http://www.who.int/genomics/FullReport.pdf  (citing 
JAMES BOYLE, SHAMANS, SOFTWARE & SPLEENS:  LAW AND THE CONSTRUCTION 
OF THE INFORMATION SOCIETY (1996). 
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This rule had always seemed clear enough:  inventions, yes, 
discoveries, no.  But we now enter into a time where the dichotomy 
between invention and discovery has become murky.  Nature is being 
put to use.  
The patenting of DNA presents an interesting point for 
consideration, because it is a topic about which there is great polarity 
in views, not only about its effects on research and access, but also 
due to more basic misgivings about whether DNA is the right sort of 
thing to patent.2  
 Natural things are being used in unnatural ways, and we, as a 
culture, are trying to handle this mash-up in the most practical of 
ways, without compromising the integrity of the patent system. 
 The patenting of genetic materials has brought forth many 
considerations.  Not only has this practice caused us to reconsider the 
line where discovery ends and creation begins, but also several issues 
have arisen regarding the current patent standards used to determine 
when inventions can be patented.  This note considers the current 
state of affairs regarding patentability in the field of biotechnology, 
especially that of genes and DNA.3  Part II gives a brief background 
of patents in general, including the requirements that must be met for 
a patent to be granted, the way in which the patent process works, 
and the options available to a patent holder once a patent has been 
granted.4  Part III explores the history of biotechnology patents.5  Part 
IV takes a look at the relationship between patents and 
biotechnology, and sheds light on some of the common arguments 
both in favor of and against the patenting of genetic material.6  Part V 
investigates solutions proposed to remedy the problems raised in Part 
III, and considers a different approach to fixing the patent system as 
                                                            
2 WORLD HEALTH ORG., supra note 1 at 48. 
3 Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 133 S. Ct. 2107, 
2111 (2013).  The human genome consists of approximately 22,000 genes packed 
into twenty-three pairs of chromosomes. Each gene is encoded as DNA, which 
takes the shape of the familiar “double helix” that doctors James Watson and 
Francis Crick first described in 1953. Each “cross-bar” in the DNA helix consists 
of two chemically joined nucleotides. Id. 
4 See infra Part II and accompanying notes 8-76. 
5 See infra Part III and accompanying notes 77-150. 
6 See infra Part IV and accompanying notes 151-197. 
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it relates to biotechnology.7  Part VI concludes this note by proposing 
a slight adaptation to the existing patent system.8 
 
II. BACKGROUND 
 
A. What is a Patent? 
 
“Patents were created as a way to provide financial incentives for 
inventors to undertake research, by allowing them to exclude 
competitors from exploiting their invention for a specified period of 
time.”9  Inventors are given a fair opportunity to commercialize and 
make profits as a result of their efforts.10  Patent holders are given 
temporary rights that act as a fence blocking off others who try to 
access the subject of the patent without a license.11  The primary 
objectives of the patent system are:  (1) to encourage the disclosure 
of technological advances and findings to the public, and (2) to 
incentivize inventors by rewarding their efforts.12  In the United 
States, patent protection arises from Congress’s Constitutional 
authority “[t]o promote the Progress of … useful Arts, by securing 
for limited Times to … Inventors the exclusive Right to their … 
Discoveries.”13  Making use of this power, Congress enacted Title 35 
of the United States Code, which governs all United States patent 
law.14  There are four parts within the title.15  Within those four parts, 
thirty-seven chapters with 376 sections can be found.16 Part I 
establishes the United States Patent and Trademark Office 
                                                            
7 See infra Part V and accompanying notes 198-249. 
8 See infra Part V.  
9 WORLD HEALTH ORG., supra note 1 at 9. 
10 See id. 
11 See id. 
12 Sara Dastgheib-Vinarov, A Higher Nonobviousness Standard for Gene 
Patents: Protecting Biomedical Research from the Big Chill, 4 MARQ. INTELL. 
PROP. L. REV. 143 (2000). 
13 U.S. CONST. art. I, § 8, cl. 8. 
14 35 U.S.C §§ 1-376. 
15 Id. 
16 Id. 
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(USPTO)17 and gives the USPTO the powers necessary to run the 
United States patent system.18   As defined by the USPTO: 
A patent is a property right granted by the Government of the 
United States of America to an inventor ‘to exclude others from 
making, using, offering for sale, or selling the invention throughout 
the United States or importing the invention into the United States’ 
for a limited time in exchange for public disclosure of the invention 
when the patent is granted.19 
In other words, a patent holder is granted the sole right to exclude 
others from making, using, or selling an invention covered by the 
patent.20  This right is often for a period of twenty years, assuming a 
request for renewal is properly filed and all applicable fees are paid 
on time.21   
Patent applications are reviewed by the Patent and Trademark 
office to ensure that they meet all requirements, including patentable 
subject matter,22 utility,23 novelty,24 and nonobviousness.252627  
                                                            
17 Id. 
18 Id. 
19 General Information Concerning Patents, UNITED STATES PATENT AND 
TRADEMARK OFFICE (Dec. 8, 2014 9:12 AM ET), http://www.uspto.gov/patents-
getting-started/general-information-concerning-patents. 
20 PATENT LAW BASICS § 6:1. 
21 Id. 
22 A patent is granted to “[w]hoever invents or discovers any new and useful 
process, machine, manufacture, or composition of matter, or any new and useful 
improvement thereof,” subject to the additional requirements of the Patent Act.  35 
U.S.C. § 101. 
23 “The utility of most mechanical inventions is apparent from an examination 
of their structures. Consequently, their utility (or, more precisely, their 
operativeness) is presumed.”  PATENT LAW BASICS § 8:6 (emphasis added).  Some 
practical utility for the product of a chemical process must either be apparent to one 
skilled in the art or be disclosed in the specification for a patent application with 
claims directed to such process to satisfy the utility requirement.  PATENT LAW 
BASICS § 8:7 (emphasis added). 
24  PATENT LAW BASICS § 7:1.  “[35 U.S.C.A. § 102] sets forth the novelty 
requirement by spelling out just what types of activity negate novelty. It declares: 
A person shall be entitled to a patent unless— 
(a) the invention was known or used by others in this country . . . or (b) the 
invention was patented or described in a printed publication in this or a foreign 
country or in public use or on sale in this country, more than one year prior to the 
date of the application for patent in the United States, or (c) he has abandoned the 
invention, or (d) the invention was first patented or caused to be patented, or was 
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Section 101 of 35 U.S.C. defines subject matter that is patentable.28  
A claim must fit in one and only one of four categories in order to be 
proper.29  “These four categories of patentable inventions include 
manufacture, machine, composition of matter, and process.”30  
Patentable subjects include products,31 processes, products-by-
processes, and living subject matter.32  A product is a “new, useful 
and non-obvious machine, manufacture and composition of 
matter.”33  Processes are “new, useful and non-obvious way[s] of 
                                                            
the subject of an inventor's certificate, by the applicant or his legal representatives 
or assigns in a foreign country prior to the date of the application for patent or 
inventor's certificate filed more than twelve months before the filing of the 
application in the United States, or (e) the invention was described in . . . (1) an 
application for patent . . . (2) a patent granted on an application for patent by 
another filed in the United States before the invention by the applicant for patent . . 
. .” Id. 
25 An invention does not satisfy the nonobvious requirement  
 if the differences between the subject matter sought to be patented 
and the prior art are such that  the subject matter as a whole would have 
been obvious at the time the invention was made to a  person having 
ordinary skill in the art to which the said subject matter pertains.   
35 U.S.C.A. § 103 (a). 
26  Additionally, 35 U.S.C. § 112(a) refers to an enablement requirement. The 
Enablement Requirement, U.S. PAT. AND TRADEMARK OFF. (March 27, 2014 
10:10:34),http://www.uspto.gov/web/offices/pac/mpep/s2164.html.  “The invention 
that one skilled in the art must be enabled to make and use is that defined by the 
claim(s) of the particular application or patent.”  Id.  Also, “In addition, the 
specification must provide a ‘written description of the invention’ disclosing 
sufficient information to enable one of ordinary skill in the art to make and use the 
invention, and must present the ‘best mode’ contemplated by the inventor for the 
design or operation of that invention.” Dastgheib-Vinarov, supra note 12 at 150 
(citing DONALD S. CHISUM ET AL., PRINCIPLES OF PATENT LAW 71 (1998)). 
27 Becca Alley, The Biotechnology Process Patent Act of 1995: Providing 
Unresolved and Unrecognized Dilemmas in U.S. Patent Law, 12 J. INTELL. PROP. 
L. 229 (2004). 
28 35 U.S.C. § 101. 
29 PATENT ACADEMY, PASSING THE PATENT BAR -A BASIC REFERENCE GUIDE, 
227-229 (2013) (ebook).. 
30 Id. 
31 Product patents to cover, for example, chemicals, formulations, equipment 
and diagnostic kits.  An invention covered by a product patent cannot be 
reproduced without a license, even if a different method is used to make it. See Id. 
32 Id. 
33 Id. 
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doing, making and using something.”34  A new process for creating a 
product may be patented even if the product itself is.35  The opposite 
of this concept is found in product-by-process inventions, which 
occurs when a product is patentable, but the process is not.36  “Living 
subject matter is patentable, but only if human ingenuity is used to 
invent the new matter.”37  If the living subject matter is not a result of 
human ingenuity, then the naturally occurring living subject matter 
may not be patented.38  Today, the constitution of existing “in nature” 
is understood to be narrow in patent law in many countries.39 “In 
nature” literally means what exists in nature; that is, what exists in its 
un-isolated form.40  Methods in which things are accomplished, 
designs, and plants (to a certain extent) all fall within the range of 
patentability.41   
Unpatentable material is classified as a discovery or some subject 
matter in which the novel aspects of which require mental activity.42  
This may include naturally occurring materials or organisms, or 
inventions encompassing a human being at its broadest reasonable 
interpretation.43  Laws of mathematics, physics, and processes that 
depend on these laws are unpatentable.44  Additionally, printed 
matter, methods of doing business, or mental processes are also 
unpatentable.45 
Section 101 of 35 U.S.C requires a prima facie showing of utility 
prior to the granting of a patent.46  “This showing must be 
                                                            
34 Id. 
35 PATENT ACADEMY, PASSING THE PATENT BAR -A BASIC REFERENCE GUIDE, 
227-229 (2013) (ebook). 
36 Id. 
37 Id. 
38 Id. 
39 WORLD HEALTH ORG., supra note 1 at 10. 
40  Id. 
41  PATENT ACADEMY, PASSING THE PATENT BAR -A BASIC REFERENCE GUIDE, 
227-229 (2013) (ebook). 
42 PATENT ACADEMY, PASSING THE PATENT BAR -A BASIC REFERENCE GUIDE, 
237 (2013) (ebook). 
43 See Id. 
44 See Id. 
45 See Id. 
46 35 U.S.C. § 101. 
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accompanied by sufficient evidence to support the utility, or 
usefulness of the material.”47  Additionally, it is required that the 
material be novel, or new.48  “While all . . . requirements are 
necessary for patentability, many judges and scholars regard 
nonobviousness as the key requirement, in part, because it is 
frequently the most challenging to prove.”49  Obviousness has been 
determined on a case-by-case basis, and in making this determination 
the court must determine the scope and content of previous patents; 
differences between those previous patents and the patent at issue; 
and the level of skill involved in creating the patentable invention.50  
In layman’s terms, the first paragraph of section 103 of 35 U.S.C. 
states that a new invention is not patentable if the invention would 
have been obvious to a person skilled in the art to which the 
invention pertains.51   
 
B.  Filing a Patent with the USPTO 
 
The first step in the patent process is to conduct a patent search to 
determine whether an invention is likely to be able to be protected.52  
Inventions that have not yet been patented may be eligible for 
patentability.53  Once it is determined that a particular invention has 
not yet been patented, the next step is to determine what type of 
application to file.54  Applications may differ depending whether a 
design patent,55 a plant patent,56 or, most commonly, a utility patent57 
                                                            
47 PATENT ACADEMY, PASSING THE PATENT BAR -A BASIC REFERENCE GUIDE, 
237 (2013) (ebook).  
48 Id. 
49 Dastgheib-Vinarov, supra note 12 at 151-52. 
50  See infra Part IV for proposed changes in the treatment of the nonobvious 
requirement in the field of biotechnology. 
51 See Id. 
52 Patents, Patent Process Overview, U.S. PAT. AND TRADEMARK OFF. (Nov. 
24, 2014 2:40 PM ET), http://www.uspto.gov/patents/process/ppo_textonly.jsp. 
53 Id. 
54 Id. 
55  “[A] ‘design patent’ protects the way an article looks (35 U.S.C. 171). 
“Technology Center 2900, Design Patent Application Guide, U.S.  PAT. 
&TRADEMARK OFF. (Aug. 13, 2012 10:42 AM ET), http://www.uspto.gov/patents-
getting-started/patent-basics/types-patent-applications/design-patent-application-
guide#def. 
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is needed.58  The text found in a patent must include “patent claims 
that define the subject matter of the invention, as well as all the 
elements, features and critical aspects of the invention, so that a 
person trained in the relevant scientific discipline should be able to 
replicate the invention.”59  The claims in the application define the 
patent’s scope, or in other words, how expansive the protection that 
is given must be.60  An additional consideration is the type of 
coverage that will be needed, for the process may vary depending on 
whether international or United States domestic protection is 
needed.61  If filing in the United States, an individual seeking a patent 
must also decide whether a provisional62 or a nonprovisional63 
application is most ideal.64  Applications may then be filed pro se or 
through a registered attorney or patent agent.65  After filing, the 
                                                            
56 “A plant patent is granted by the Government to an inventor (or the 
inventor's heirs or assigns) who has invented or discovered and asexually 
reproduced a distinct and new variety of plant, other than a tuber propagated plant 
or a plant found in an uncultivated state.”  Technology Center 1600, General 
Information About 35 U.S.C. 161 Plant Patents, U.S. PAT. & TRADEMARK OFF. 
(Feb. 20, 2015 4:05 PM ET), http://www.uspto.gov/patents-getting-started/patent-
basics/types-patent-applications/general-information-about-35-usc-161. 
57 “In general terms, a ‘utility patent’ protects the way an article is used and 
works (35 U.S.C. 101).”  Technology Center 2900, supra note 56. 
58  Patents, supra note 52.  
59  WORLD HEALTH ORG., supra note 1. 
60  Id. 
61   Patents, supra note 52.  
62  A provisional application for patent has a pendency lasting 12 months from 
the date the provisional application is filed. The 12-month pendency period cannot 
be extended. Therefore, an applicant who files a provisional application must file a 
corresponding nonprovisional application for patent (nonprovisional application) 
during the 12-month pendency period of the provisional application in order to 
benefit from the earlier filing of the provisional application.  Provisional 
Application for Patent, U.S. PAT. & TRADEMARK OFF.  (Jan. 12, 2015 2:11 PM 
ET), http://www.uspto.gov/patents/resources/types/provapp.jsp. 
63 A non-provisional patent application, once filed, merely establishes the 
filing date of the patent and begins the patent examination process.  Id. 
64  Patents, supra note 52. 
65  Id.  One major advantage to filing a pro se application is the avoidance of 
costly attorney’s fees.  Depending on the amount of technology involved in the 
patent, attorney’s may charge anywhere form $5,000.00 to upwards of $15,000.00 
to see the application process through.  Gene Quinn, The Cost of Obtaining a 
Patent in the US, IPWATCHDOG (Apr.4, 2015), 
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USPTO examines the application to either grant or reject the 
application.66  If rejected, the patent applicant may reply with a 
request to reconsider and may appeal as necessary.67  Once granted, 
the applicant must pay an issue fee and a publication fee.68  To 
preserve a patent for the years-to-come, maintenance fees are due 
three-and-a-half, seven-and-a-half, and eleven-and-a-half years after 
the original grant.69   
 
C.  Licensing patented inventions 
 
Patent holders are given at least two choices as to how to exercise 
his or her exclusive rights.70  “First, the patent holder may decide to 
be the sole user of the patented invention and exclude all others from 
its manufacture, use, or sale.”71  In the alternative, the patent holder 
may choose to grant a license to others, giving them “the right to use 
the invention under agreed-upon terms.”72  The patent holder may 
grant an “exclusive [license] to one licensee, or a non-exclusive 
license to several licensees.”73  “Exclusive licenses can include 
exemptions, for example for humanitarian or research use.”74  
However a patent holder chooses to use the patent, “the patent holder 
is able to [create revenue either through the sale of the patented 
invention] and services, or through royalties obtained from licensees” 
                                                            
http://www.ipwatchdog.com/2015/04/04/the-cost-of-obtaining-a-patent-in-the-
us/id=56485/. 
66  Patents, supra note 52. 
67  Id. 
68  Id.  Patent application filing fees may range from $140.00 to $780.00.  The 
major factor in determining the cost of a patent application is the complexity of the 
patent.  Additional up-front fees and maintenance fees may result in a patent filing 
process that costs thousands of dollars. USPTO Fee Schedule, U.S. PAT. & 
TRADEMARK OFF. (Feb. 4, 2015 6:14 PM ET), 
http://www.uspto.gov/web/offices/ac/qs/ope/fee010114.htm#patapp. 
69  Patents, supra note 52.  
70 WORLD HEALTH ORG.supra note 1 at 13. 
71 Id. 
72 Id. 
73 Id. 
74 Id. 
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using the patent.75  This is the financial incentive that makes up the 
foundation of patent law.76 
 
III.  THE FIELD OF BIOTECHNOLOGY 
 
A.  The Patentability of Biotechnology 
 
“At its simplest, biotechnology is technology based on biology - 
biotechnology harnesses cellular and biomolecular processes to 
develop technologies and products that help improve our lives and 
the health of our planet.”77  In the recent decades, the field of 
biotechnology has been stirring up much controversy in the patent 
word.  “In recent years, this history has been marked by dramatic 
changes in the way that lawmakers and courts view and interpret the 
system.”78  Biotech generally concerns the application of cellular and 
molecular biology to make or modify products and processes for 
specific use.79  Biotechnology brings unique challenges to the topic 
of patentability, as often biotechnology patents often operate within a 
grey area dealing with living organisms.80  Traditionally, living 
organisms were truly only products of nature, and therefore remained 
unpatentable.81  However, this is no longer the case since advances in 
science have resulted in the technology to modify and develop 
organisms.82 
The manipulation of living or biologically active materially has 
contributed greatly to humanity,83 especially with advances made in 
                                                            
75 WORLD HEALTH ORG.supra note 1 at 13. 
76 Id.  
77What is Biotechnology?, BIOTECHNOLOGY INDUS. ORG., 
https://www.bio.org/articles/what-biotechnology (last visited Oct. 22, 2015). 
78 Id. at 11. 
79 Cf. 1 BIOTECHNOLOGY AND THE LAW § 1:1, Westlaw (database updated June 
2015). 
80 Jake Gipson, Patentable Subject Matter: A Myriad of Problems, 65 ALA. L. 
REV. 815 (2014). 
81 Id. 
82 Id. 
83 “Since biotechnological processes are inherently low-energy and renewable, 
they are being utilized to provide solutions for some of the world's problems. In 
agriculture, the bacterium Pseudomonas syringae has been modified to impart frost 
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the agriculture and pharmaceutical fields.84  For example, patents 
have been procured in order to diagnose patients with genetic 
mutations using deoxyribonucleic acid (DNA).85 All genetic material 
is comprised of the biochemical substance known as DNA,86 and this 
includes the genetic material found in all living organisms.87  DNA is 
a double helix shaped molecule, made of two linear chains made 
from adenine, guanine, cytosine, and thymine nucleotide bases.88   
An ordered sequence of these nucleotide bases within the DNA, 
located in a particular position on a particular chromosome may 
constitute a gene.89  These genes encode a specific functional product 
such as a protein.90 “One of the challenges with respect to DNA is 
that it is an upstream tool for basic research (e.g. PCR91), a medically 
                                                            
protection to plants by deleting a gene for a protein that nucleates ice crystal 
formation.” Dastgheib-Vinarov, supra note 12 at 146.  Also, “Industrial 
applications of biotechnology include engineering microorganisms to be used to 
clean up oil20 and chemical spills. Bioengineered biodegradable plastics offer 
solutions to the world's growing waste disposal problem.”  Id. at 147.  “Medical 
benefits of biotechnology include the development of new drugs and enhanced 
production of old drugs that combat cancer, A.I.D.S., dwarfism, diabetes, hepatitis, 
and even aging.”  Ned Hettinger, Patenting Life: Biotechnology, Intellectual 
Property, and Environmental Ethics, 22 B.C. ENVTL. AFF. L. REV. 267, 272 (1995). 
84 Biotechnology, WORLD INTELL. PROP. ORG., 
http://www.wipo.int/patents/en/topics/biotechnology.html. 
85 Christopher Bergin, Take Off Your Genes and Let the Doctor Have A Look: 
Why the Mayo and Myriad Decisions Have Invalidated Method Claims for Genetic 
Diagnostic Testing, 63 AM. U. L. REV. 173, 177 (2013) (“[D]iagnostic patents have 
three basic steps: (1) obtaining a DNA sample from a patient, thereby establishing a 
providing, collecting, or obtaining step, (2) sequencing that DNA sample, and (3) 
comparing the patient's DNA sequence to other known wild-type and mutant 
strands to determine if the patient has a mutation.”). Id. 
86 WORLD HEALTH ORG., supra note 1 at 2. 
87 www.genome.gov 
88 Id.  
89 Id. 
90 Id. 
91 “PCR (short for Polymerase Chain Reaction) is a relatively simple and 
inexpensive tool that you can use to focus in on a segment of DNA and copy it 
billions of times over. PCR is used every day to diagnose diseases, identify bacteria 
and viruses, match criminals to crime scenes, and in many other ways.”  PCR, 
LEARN GENETICS,  (2015), http://learn.genetics.utah.edu/content/labs/pcr/. 
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valuable product (e.g. gene therapy92), as well as vital information 
about the molecular basis for disease.”93  The basis for studies to 
develop therapeutics, and for immediate use in laboratories, is 
therefore sometimes dependent on some individual patents.94  One of 
the DNA’s most significant contributions has been the 
pharmaceutical use of DNA to develop large-molecule proteins, such 
as insulin, growth hormone, growth factors, and blood-clotting 
factors, to treat serious diseases.95  Additionally, DNA has embedded 
within it, information about the future of an individual’s health.96  
“DNA genetic testing involves the analysis of DNA in order to 
determine the presence a gene associated with a particular disease.”97  
These tests come in four general varieties:  carrier testing98, prenatal 
testing99, diagnostic testing100, and predictive testing101.102  It is clear, 
that the isolation of genes from DNA is a very valuable tool to the 
                                                            
92 “Gene therapy could be a way to fix a genetic problem at its source. By 
adding a corrected copy of a defective gene, gene therapy promises to help diseased 
tissues and organs work properly. This approach is different from traditional drug-
based approaches, which may treat symptoms but not the underlying genetic 
problems.” What is Gene Therapy?, LEARN.GENETICS (2015), 
http://learn.genetics.utah.edu/content/genetherapy/gtintro/.  
93 WORLD HEALTH ORG., supra note 1 at 48.  
94 Id. 
95 Id. 
96 Id.  
97 Id. 
98  “Carrier testing determines if the person tested, who does not himself have 
the disease, carries a gene for the disease. If two carriers have a child together, 
there is a high probability that their offspring will have the disease.”  Id. 
99  “Prenatal testing determines whether a fetus is affected with a genetic 
abnormality causing a particular condition. Embryos may also be tested during in 
vitro fertilization before being surgically implanted into the womb; this is called 
pre-implantation diagnosis. For technical reasons, the latter method is not widely 
practiced.” WORLD HEALTH ORG., supra note 1 at 48. 
100  “Diagnostic testing determines whether the tested individual in fact has a 
particular genetic condition or a genetic predisposition for acquiring the condition 
later in life.” Id. 
101  “Predictive testing determines the presence in asymptomatic individuals of 
an abnormal gene that will lead to a disease in the future, or of a genetic 
predisposition for acquiring the condition later in life, in interaction with 
environmental factors.” Id. 
102  Id. at 4. 
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medical community. 
The USPTO states that, “a patent on a gene covers the isolated 
and purified gene but does not cover the gene as it occurs in 
nature.”103 According to this view, what distinguishes a DNA 
sequence that exists naturally in a cell or organism from a patentable 
DNA sequence is that the former owes nothing of its existence to a 
human inventor, while the latter would not exist without some form 
however minimal of human intervention.104  
Once an isolated gene has been deemed an “invention” for patent 
purposes, the gene sequence must still have some distinguishable 
utility, and some sort of invented step must be demonstrated to meet 
the nonobvious standard.105  “In general, DNA patents claim at least 
one of the following four applications of DNA sequences: diagnostic 
testing, research tools or methods, gene therapy or methods, or the 
production of therapeutic proteins to be used as medicines.”106   
In some areas, there is evidence that an increase in the amount of 
patents has not been accompanied by a proliferation of medical 
applications.107 Undoubtedly, the lag between patents and medical 
applications is in some ways attributable to the complex nature of the 
science, as well as to technical issues.108 “[I]t is unclear how much is 
related, if only indirectly, to a failure of incentive mechanisms, 
including patents, to generate new and useful products and 
services.”109 
 
B.  Ethical Objections 
 
 Many ethical concerns have been expressed regarding the 
modification of human biological material.110  “It has been claimed 
that it is unacceptable for people to have ‘proprietary rights in living 
                                                            
103  Id. 
104  WORLD HEALTH ORG., supra note 1 at 4. 
105  Id. 
106  Id. 
107  Id. at 48.  
108 Id. 
109 WORLD HEALTH ORG., supra note 1 at 48.  
110  Id. at 30. 
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beings and tissues,’111 and that market logic now holds sway over the 
use of living organisms (or their component parts).”112 The United 
Nations Educational, Scientific and Cultural Organization’s 
Declaration on the Human Genome and Human Rights makes the 
claim that the human genome is the “common heritage of 
humankind.”113 This implies that DNA goes beyond existence as 
regular biological molecule, and that it also includes some sort of 
special character.114 “Human DNA is common to all human beings 
(DNA itself is common to all living things), past and present.  
Therefore, DNA is foundational not only biologically, but also 
historically and even morally; in its’ significance.”115 
 Genetic material, in essence is knowledge and information, and 
typically knowledge and information is seen to be beneficial to the 
public.116 “Genomics knowledge is nonrivalrous in consumption (not 
depleted by use), and is usually made public by genomics databases 
on the Internet and journal publication, as was the case with the 
malaria and mosquito genome.”117 “It is a global public good in the 
sense of the knowledge not being bound by national border, in 
discovery, transmission, or use. Further, the global public-good 
nature of genomics is reflected in the way in which the Human 
Genome Project was funded and undertaken.”118 
The Agreement on Trade-Related Aspects of Intellectual Property 
Rights (TRIPS Agreement) leaves space for countries to do precisely 
this. According to Article 27 of TRIPS: 
Members may exclude from patentability inventions, the 
prevention within their territory of the commercial exploitation of 
which is necessary to protect ordre public or morality, including to 
protect human, animal or plant life or health or to avoid serious 
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114 WORLD HEALTH ORG., supra note 1 at 31. 
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116 Id. at 32. 
117 Id.  
118  Id. 
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prejudice to the environment, provided that such exclusion is not 
made merely because the exploitation is prohibited by their law.119 
 
C.  Legal Issues 
 
 It is often argued that DNA, in certain cases, is not suitable as 
patentable subject matter when the legal requirements for patents are 
applied strictly.120  One concern is that because genetic material is 
essentially information; therefore, DNA’s value is primarily in the 
information within the material and not in the material qualities of 
the DNA itself.121  Given this viewpoint, this represents a departure 
from patent doctrine, “. . . which is based on an agreement to disclose 
information in exchange for giving the inventors’ rights over the 
material invention.”122  “If DNA itself has value not only as material, 
but also, if not primarily, as information, this moves away from the 
usual range of patentable material and presents a new challenge for 
those who need access to the information.”123 
 In the first instance, there has been concern about the requirement 
of an “inventive step”, given that the sequencing of DNA, once a 
laborious manual task, has become a highly automated and routine 
part of laboratory practice. In the United States, the Court of Appeals 
for the Federal Circuit’s interpretation of the “non-obviousness” 
standard has explicitly denied that the difficulty or complexity of 
invention matters at all in the determination of patentability. 
Additionally, there has been questioning of the granting of patents for 
sequences of questionable or limited utility. Some of this controversy 
has abated with the USPTO’s 2001 guidelines on expressed sequence 
tags (ESTs, short pieces of DNA that help to identify when particular 
genes are being expressed in cells), which tighten the specifications 
regarding what constitutes “utility”.124   
The amount of creative energy and the technical difficulty 
                                                            
119  Part II — Standards concerning the availability, scope and use of 
Intellectual Property Rights, WORLD TRADE ORG (2015) 
http://www.wto.org/english/docs_e/legal_e/27-trips_04c_e.htm. 
120  WORLD HEALTH ORG., supra note 1 at 10. 
121 Id.  
122 Id.  
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required to acquire this genetic knowledge may be the factor 
determining whether or not something may be patented.125 Some 
consider that the isolation and sequencing of genetic material takes 
little creative energy and difficulty, and requires only a basic 
competence.126 On the other hand, it may take great effort in order to 
identify the link between a disease and a particular gene depending 
on the “complexity of the interactions involved.”127 
 
D.  Biotechnology and the “Big Freeze” 
 
“Entities from industrialized countries currently hold 97% of all 
patents worldwide.  The rise in patents in biotechnology has been 
particularly dramatic, climbing by 15% per annum from 1990 to 
2000 at the UPTO.”128  The growth of patents in the biotechnology 
field has been heavily influenced by the public sector.129  “For 
example, public institutions in Europe and the United States own 
30% of all the patents for DNA sequences filed between 1996 and 
1999.”130  And “start-up companies have a higher share of 
biotechnology patents than do large, established pharmaceutical 
companies.”131 
The most basic argument in favor of granting these biotechnology 
patents is, as applicable to all types of patents, simply that people are 
naturally entitled to the fruits of their labor.132  Patents are arguably 
necessary to make innovation profitable because patents grant the 
opportunity for a patent holder to exclusively profit from her work.133  
Locating, isolating, and describing biomolecular matter requires 
considerable ingenuity, and, as a result, the biotech industry argues 
that, without strong patent protection, firms could not justify the risk, 
time, energy, and money necessary to create new pharmaceutical and 
                                                            
125 WORLD HEALTH ORG., supra note 1 at 36. 
126 Id. 
127  Id. 
128  Id. at 20. 
129 Id.  
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132 Ned Hettinger, Patenting Life: Biotechnology, Intellectual Property, and 
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agricultural products.134  Additionally, companies argue that, if they 
are to continue producing new drugs and therapies for the treatment 
of disease, the public may be best served by allowing life forms and 
their structural components to be patented as inventions.135  This 
protection may be particularly critical for start-up biotechnology 
companies that need to attract capital; for intellectual property is 
often the sole asset of the company.136  A shift in the way in which 
organizations do research has been sparked by this rapid increase in 
biotechnology patents.137  
According to a recent report by the Organisation for Economic 
Cooperation and Development: Not only have new types of 
inventions—software, genetic, and business methods—been deemed 
patentable by some patent offices, but the ability of patent holders to 
protect and enforce their rights has also increased, leading many to 
call the past two decades a pro-patent policy era.138   
While the current system promotes innovation by rewarding 
innovators early in the developmental stages, this early reward “could 
hinder those conducting important research or providing needed 
services downstream, and can inhibit cumulative innovation.”139 This 
may be the result when licenses for patents granted prematurely 
restrict the amount of research that may be conducted.140 
 Those opposed to living material patents specifically oppose 
those patents granted on single-function genes.141  Often, these 
single-function genes must be combined with other genes in order for 
research to progress, and this often creates a “freezing” effect on 
biotechnology research because permission must be granted before 
any previously patented genes may be used to further the research.142  
Thus, granting patents on genes when they are pre-market or while 
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139 WORLD HEALTH ORG., supra note 1 at 12 
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141 Graeme Suthers, Gene patents: “Discoveries not inventions”, CANCER 
INSTITUTE NSW (Sep. 28, 2010), http://www.cancerinstitute.org.au/news-
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they are still upstream in the research process may be stifling life-
saving innovations further downstream in the course of research and 
development.143  Furthermore, the increased protection on genes may 
be raising the overall cost of research and development because a 
company that wishes to use the results of other research is bound to 
incur large costs in acquiring licenses to use other patents.144  As a 
result, the field of biotechnology faces the “tragedy of the 
anticommons,” where a resource is prone to underuse when multiple 
owners each have a right to exclude others from a scarce resource 
and no one has an effective privilege of use.145 “This debate reflects a 
fundamental controversy about whether DNA ought to be treated 
specially, or the same as any other molecule.”146   
 
IV. THE HISTORY BEHIND GENE PATENTS 
 
In 1953, James Watson, Francis Crick, and Maurice Wilkins first 
discovered DNA and pulled at the first thread to unravel the mystery 
blanketing genetics and heredity.147  This scientific leap was made 
possible by several scientific breakthroughs, including: 
[P]rogress made by X-ray crystallographers in studying organic 
macromolecules; the growing evidence supplied by geneticists that it 
was DNA, not protein, in chromosomes that was responsible for 
heredity; Erwin Chargaff’s experimental finding that there are equal 
numbers of A and T bases and of G and C bases in DNA; and Linus 
Pauling’s discovery that the molecules of some proteins have helical 
shapes—arrived at through the use of atomic models and a keen 
knowledge of the possible disposition of various atoms.148 
                                                            
143 Biotechnology, WORLD INTELL. PROP. ORG. (Feb. 2, 2015, 9:10 AM), 
http://www.wipo.int/patents/en/topics/biotechnology.html 
144 Graham Dutfield, Intellectual Property and Basic Research: Discovery vs 
Invention, SCIDEV (Jan. 05, 2003), http://www.scidev.net/global/policy-
brief/intellectual-property-and-basic-research-discovery.html. 
145 Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation? 
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146 WORLD HEALTH ORG., supra note 1 at 18.  
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Jointly, Watson, Crick, and Wilkins received the 1962 Nobel 
Prize in physiology or medicine for their contribution to science.149 
In 1980, the Supreme Court held that a genetically engineered 
strain of bacteria “with markedly different characteristics from any 
found in nature” was patentable.150  Patents for plants, animals, and 
micro-organisms such as cell lines and DNA became increasingly 
common, for Congress began encouraging universities and other 
institutions to patent discoveries arising from federally supported 
research and development.151   
A decade later, the Supreme Court of California provided the first 
clear rule regarding an individual’s right to his or her own genetic 
material in Moore v. Regents of University of California.152  In 
Moore, a leukemia patient underwent treatment at the UCLA Medical 
Center.153  It was later discovered by the patient that his white blood 
cells had been used to create a cell line that would be used for the 
medical center’s financial benefit.154  When Regents of the university 
applied for a patent on the cell line,155 the patient filed suit against his 
                                                            
149 Id. 
150 Diamond v. Chakrabarty, 447 U.S. 303 (1980).  Patent examiners at the 
Patent and Trademark Office rejected Chakrabarty’s patent application for a 
bacterium into which he introduced “naturally occurring plasmids” on the grounds 
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of the Patent Act.”  Donna M. Gitter, International Conflicts over Patenting 
Human DNA Sequences in the United States and the European Union: An 
Argument for Compulsory Licensing and A Fair-Use Exemption, 76 N.Y.U. L. 
REV. 1623, 1640 (2001).  On appeal, the Supreme Court held in a five-to-four 
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protection as a new “manufacture” or “composition of matter” under section 101 of 
the Patent Act.  Id. at 1640-41.  “[Chakrabarty’s] micro-organism plainly qualifies 
as patentable subject matter. His claim is not to a hitherto unknown natural 
phenomenon, but to a nonnaturally occurring manufacture or composition of 
matter—a product of human ingenuity ‘having a distinctive name, character [and] 
use.’” Diamond, 447 U.S. 303, 309-10, (1980) (quoting Hartranft v. Wiegmann, 
121 U.S. 609, 615, 7 S.Ct. 1240 (1887)). 
151 SCIDEVNET (2015) www.scidev.net. 
152 Moore v. Regents of Univ. of California, 793 P.2d 479 (1990). 
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155 U.S. Patent No.: US4438032, 4,438,032 (filed Mar. 20, 1984).. 
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physician and the Regents of the University of California.156  To the 
patient’s dismay, the court found that the patient had no property 
rights to his discarded cells and was not entitled to any profits 
resulting from the cell line.157 
A year later, biotechnology patentability broadened when the 
Federal Circuit upheld the patentability of human DNA sequences 
that are “purified and isolated” from the original object in nature.158  
Then in 1995, the United States Court of Appeals for the Federal 
Circuit ruled on a controversial issue in In re Deuel.159  Deuel used 
uterine and placental cells to isolate the DNA and growth factor 
sequences of a protein called heparin-binding growth factor 
(“HBGF”).  Deuel’s claims were rejected for “obviousness” after the 
patent examiner and Board determined that the HGBF was the same 
as another protein, heparin-binding brain mitogen (“HBBM”).160  
Deuel appealed the rejection.161  The Court ultimately ruled in favor 
of Deuel, finding that, regardless of whether Deuel used the general 
method for isolating DNA or not, the location of the protein was not 
aided by the discovery of the prior HBBM.162  Thus, the DNA 
molecules encoding the protein were nonobvious under section 103 
of the Patent Act.163 
In 1996, however, the patentability trend took a turn when the 
“Strategy Meetings on Human Genome Sequencing” resulted in an 
agreement that all raw sequence data from the human genome 
sequencing efforts should be “freely available [to] the public 
domain.”164  The organization that coordinated this effort was the 
Human Genome Organisation (HUGO).165  “Partners in this initiative 
[have] articulated their commitment to making their results rapidly 
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available, and to placing them in the public domain.”166 “British 
Prime Minister Tony Blair and then-President of the United States 
Bill Clinton issued a joint statement, affirming that: ‘To realize the 
full promise of this research, raw fundamental data on the human 
genome . . . should be made freely available to scientists 
everywhere.’”167 The patenting of DNA was not ruled out.168  It was 
later added that “[i]ntellectual property protection for gene-based 
inventions will also play an important role in stimulating the 
development of important new health care products.”169  In the same 
vein, in 2001 the United States Patent Office revised its guidelines to 
emphasize that patents must show specific, substantial, and credible 
utility – a “real world context for using the invention.”170  The main 
driver of advances from the human genome was a project led by 
scientists all over the world called The Human Genome Project.171  
This project was “an approach to the large-scale sequencing and 
analysis of DNA that continues to have an enormous impact on how 
biomedical research is done in laboratories around the world.”172  
Many similar projects seeking to sequence the genomes of many 
organisms have arisen from the Human Genome Project – “from 
useful laboratory animals to deadly disease-causing agents.”173 
Although “laws of nature, natural phenomena, and abstract ideas” 
are not patentable subject matter under § 101 of the Patent Act,174 “an 
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application of a law of nature . . . to a known structure or process 
may [deserve] patent protection.”175  In 2012, the Supreme Court 
affirmed in the biotechnology world that “(1) a newly discovered law 
of nature is itself unpatentable and (2) the application of that newly 
discovered law is also normally unpatentable if the application 
merely relies upon elements already known in the art.”176  In Mayo 
Collaborative Services v. Prometheus Labs., Inc., the Court 
considered two method patents held by Promethium Labs for 
methods used to determine the appropriate amount of medication to 
administer to a patient with Crohn’s Disease.177  The Court 
conducted its inquiry by looking at each step described in the 
method178 “to consider whether any of the steps added anything to 
the law of nature that was not  
‘well-understood, routine, conventional activity.’”179  The 
“administering” step,180 the “wherein” step,181 and the final 
“determining” step182 were all considered individually.  The Court 
then evaluated the method as a whole to see if the method contributed 
anything new to the laws of nature.183  
Most recently, the Supreme Court considered the validity of gene 
patents in Association for Molecular Pathology v. Myriad Genetics, 
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Inc.184 Litigation in Myriad transpired from a global search to find 
the genetic basis for breast and ovarian cancer.185 Myriad Genetics 
was founded in 1994 as a startup company out of University of Utah, 
by scientists involved in the hunt for the BRCA genes.186 Later that 
year, Myriad filed the first patent for BRCA 1,187 and within the next 
year, Myriad had isolated and patented a second gene associated with 
breast cancer, the BRCA2 gene.188  Suit was filed against Myriad, 
seeking declaration that Myriad’s BRCA1 and BRCA2 patents were 
not patentable subject matter under § 101 of Title 35 of the United 
States Code.189  The primary plaintiff in the action was the 
Association for Molecular Pathology (AMP), which actively lobbied 
against the licensing and existence of gene patents.190  AMP argued 
that the genes were unpatentable because they were products of 
nature that had merely been isolated,191 and that no real world 
transformations occurred to the genes in the process of isolation.192  
The Court ultimately came to the holding that the process of isolating 
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DNA involves naturally occurring segments of DNA, thus precluding 
patentability.193  However, it also held that cDNA194 is not naturally 
occurring and remains patent eligible.195 
 
V. ANALYSIS:  ARE WE LOOKING IN THE RIGHT PLACE? 
 
A. The Nonobvious Requirement 
 
In response to many of the issues that have arisen from gene 
patenting, and in proposing a solution, much attention has been given 
to the nonobvious requirement.196  Whether an invention is obvious is 
determined by asking whether a person of ordinary skill in the art, 
who knew all of the invention's prior art, would have had a 
reasonable expectation that the invention would work.197  In 1966 the 
Supreme Court in Graham v. John Deer Co. looked at multiple 
factors to determine whether an invention was obvious.198  The 
analysis in Graham provided a step-by-step method of evaluating the 
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nonobvious requirement.199  First, differences in the prior art and the 
claims at issue are determined based on the scope and content of the 
prior art.200  Then, the level of ordinary skill is resolved to determine 
whether the “subject matter as a whole would have been obvious at 
the time the invention was made to a person having ordinary skill in 
the art.”201  The Court also noted that, to give light to the 
circumstances surrounding the origin of the subject matter, it might 
need to use “secondary considerations.”202   
These Graham factors remained in use from 1966 until 2007 
when the Supreme Court once again considered the nonobvious 
requirement..203  In that time, lower courts developed a “teaching, 
suggestion, or motivation” or “TSM” test that was to be applied aside 
from the Graham factors.204  In application, courts contemplated 
whether there was a suggestion or motivation to combine known 
elements in prior art references.205  The Supreme Court assessed the 
use of this TSM test in 2007 in a case called KSR Int’l Co v. Teleflex, 
Inc.,206 holding that the TSM test was too rigid in application.207  The 
Court held that “the fact that a combination was obvious to try might 
show that it was obvious under § 103,”208 which led to the obvious to 
try standard that provides the background to obviousness as it relates 
to gene patenting.209 
Much of the current patent law was developed between the 
Graham factors and the obvious to try standard.210  Regarding the 
patenting of a naturally occurring gene, the Federal Circuit concluded 
in 1970 that “an unknown compound or composition of materials 
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merely discovered from nature is not patentable.”211  In 1980, the 
Supreme Court in Diamond v. Chakrabarty allowed the patenting of 
a living organism.212  The living organism had been genetically 
altered, and the Court noted that since “Congress intended statutory 
subject matter to ‘include anything under the sun that is made by 
man,’”213 a genetically modified organism was patentable as a 
“product of human ingenuity.”214  
In 1995, “[t]he Federal Circuit held in [In re Deuel] that a “DNA 
[in ][w]hich the [p]rotein [p]roduct [i]s [h]omologous to a [k]nown 
[p]rotein [i]s [n]ot [o]bvious.”215   As discussed, Deuel had tried to 
patent a sequence that encoded a protein that was not known to 
anyone at the time.216  However, there was a similar protein with a 
known function disclosed in previous experiments.217  Because 
Deuel’s sequence shared similarity to the sequence of the previously 
disclosed protein, the USPTO rejected the patent application for 
being obvious.218 “[T]he court focused on a criterion familiar to old 
time chemists whose main way to design new compounds was 
molecular modification--structural similarity.”219  “[T]he court 
focused on the ‘consequences of genetic code's redundancy on 
DNA's obviousness, asserting that it precludes contemplation and 
conception of the exact structure of cDNA molecules.’”220  The 
Federal Circuit reversed the USPTO rejection by reasoning that 
“because of the redundancy in the genetic code, countless possible 
DNA sequences could code for the protein.”221 As a result, “a person 
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of ordinary skill in the art could not have determined the DNA 
sequence without actually doing the experiment performed in 
Deuel.”222  As it stands today, for naturally occurring DNA 
molecules, if their functions described in the patent applications 
agree “with the prediction based on its sequence homology to a 
protein with a known function, it is not patentable on the ground of 
nonobviousness.”223 But, if there is a discrepancy between the 
predicted function of a naturally occurring DNA molecule, as 
described in the patent application, and the function, as predicted 
based on its homology to a protein with a known function, it may 
meet the nonobvious standard.224 
It is no surprise that there has been much concern involving the 
nonobvious standard.  Granting exclusive rights to an obvious 
invention contributes significantly to the problems that coincide with 
gene patenting.  Concern has been expressed that if the bar is set too 
low for achieving nonobviousness, then public fear regarding genetic 
privacy will result in fewer donations of genetic information that will 
hinder research and testing.225  There are additional arguments in 
favor of a heightened standard for nonobvious that hinge on the 
availability of genetic information to researchers and scientists.226  
New strategies have been developed since the 1980’s that make it 
easier to obtain cDNA and genes in the laboratory.227  “[C]ompanies 
are using state of the art technologies from various fields to reduce 
the guesswork and increase the accuracy and certainty in performing 
previously lengthy recombinant DNA procedures.”228  Also, private 
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and public databases containing genomic research have become more 
readily available, making the “invention” of cDNA seemingly more 
obvious.229  Freely accessible databases have been made available to 
the public by the government.230  Some of these governmental 
databases “include the National Genbank, developed by the National 
Institutes of Health (NIH), and dbEST, the database for expressed 
sequence tags.”231  In the private sector, there are companies making 
money by charging for access to their sequenced gene databases.232  
To name a few:  “Incyte, ‘Sequana Therapeutics in San Diego, 
Millenium Pharmaceuticals in Cambridge, Massachusetts, and 
Myriad Genetics in Salt Lake City, Utah.’”233 
Clearly, the degree of obviousness can interfere with the 
underlying principles which give rise to the social value of 
patenting.234  The patenting of small molecules for drugs has been 
illustrative of this point.235  At times, the degree of ingenuity behind 
an invention is overshadowed in valuations in favor of the time and 
money invested in the development of the invention.236 “Patents, in 
this case, are principally to induce investment rather than to 
encourage innovation.”237 
 Once the general population seemingly accepted the notion that 
genetic material may qualify as an invention opposed to a mere 
discovery, most of the attention has been aimed at adjusting the 
nonobvious standard to remedy the problems arising from gene 
patents.  Though many great arguments have been presented, and 
many solutions have been recommended, nonobviousness is but one 
patent requirement.  Directing our attention elsewhere, and perhaps 
assessing all facets of the system, may enable us to shed light on 
additional weaknesses within the current system – the correction of 
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which may also help to alleviate the anxiety caused by genetic 
patenting. 
 
B. The Uselessness of the Utility Requirement 
 
As discussed, the main focus for those who want to better the 
current patent system has been on the nonobvious requirement.  By 
no means should the nonobvious requirement be taken lightly.  It is a 
very important aspect of the process and illuminates the policy 
behind granting patents at all.  Strong arguments have been presented 
to adjust the nonobvious requirement, and progress has been made as 
a result of those arguments.  Nonobviousness, however, is but one 
symptom to be treated in a greater illness.  For purposes of this 
Comment, let us pretend that nonobviousness is a hurdle that has 
already been cleared, and now direct our attention to the usefulness 
of these genetic patents.   Notwithstanding the other patent 
requirements, it appears that genetics patents that have been granted 
prior to the patented idea are ambiguous when it comes to their use.  
The usefulness requirement is being met on credit.  Patentees are 
granted patents on ideas that show promise, but not utility, and this 
current system is contributing greatly to icing the momentum of 
innovation. 
Two cases that illustrate this point are Myriad and Chakrabarty.  
Both cases involve patents granted for something that has been 
tweaked in the laboratory to make it different enough from the 
natural counterpart to qualify it for patent protection.  Both cases 
were analyzed through the lens of the nonobvious requirement – that 
is, it was the Court’s resolve to settle whether it was obvious to use 
naturally occurring materials in inventing something else.  The end 
result in both was the same.  The reasoning in Myriad is that, though 
DNA is found in nature, the cDNA for which a patent was sought is 
not.  Thus, the cDNA met the nonobviousness requirement.  
Similarly, in Chakrabarty, though a bacterium was found in nature, 
the genetically modified bacterium for which the patent was sought 
was not found in nature.  Therefore, the genetically modified 
bacterium was not obvious and was eligible for patent protection.   
In Chakrabarty, the genetically modified bacterium was 
developed to treat oil spills, for the bacterium had been put to use and 
was capable of breaking down crude oil.   Therein lies the key 
difference between the patent sought in Chakrabarty and the patent 
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sought in Myriad – the known usefulness of the invention. Take a 
moment to compare the language of the Chakrabarty patent to one of 
the patents at issue in Myriad.  The Chakrabarty patent states that 
“[t]he versatility of these novel [bacterium] has been demonstrated 
by the substantial extent to which degradation of such complex 
hydrocarbons as crude oil and Bunker C oil has been achieved 
thereby.”238  Myriad’s claim, on the other hand was that  
[t]he present invention relates generally to the field of human 
genetics. Specifically, the present invention relates to methods and 
materials used to isolate and detect a human breast and ovarian 
cancer predisposing gene (BRCA1), some mutant alleles of which 
cause susceptibility to cancer, in particular breast and ovarian cancer. 
More specifically, the present invention relates to germ line 
mutations in the BRCA1 gene and their use in the diagnosis of 
predisposition to breast and ovarian cancer.239   
The difference is clear that, from the language of the patents, 
Myriad had not proven the usefulness of the BRCA1 gene.  The 
patent was applied for based on a known affiliation with breast 
cancer, but only a presumption that the BRCA1 would be useful in its 
treatment.  It may be true that the presumption was strong based upon 
BRCA1’s gene sequence homology to other genes with a known 
function, but why not hold the patent applicant responsible for 
showing actual use in practice?  Would that not expand the window 
in which additional research can be conducted by third parties before 
they are required to obtain a license to use the gene? 
The current usefulness standard in general is that a new product is 
“not useful only when it is incapable of achieving any beneficial 
function or use in any application and under any consequences.”240  
In regards to new chemicals, patents are only to be granted upon the 
disclosure of some specific utility by the new chemical.241  In In re 
Kirk, the court found that the application failed to describe a useful 
invention.242  The patent application claimed that the new compounds 
could be converted into something useful, but did not make a claim 
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of usefulness regarding the new compounds themselves.243  It was 
held that the new compound was not useful in the patent sense 
because the only use of the new compound was to make other 
compounds that showed promise in being useful.244 
The bar is set slightly lower when applying to patent a 
pharmaceutical drug.  Inventors are only required to show potential 
therapeutic use in application.245 Various types of research that might 
indicate potential therapeutic benefits are disclosed in the patent 
application.246  Because testing does not necessarily involve 
experiments that accurately mimic the way in which a 
pharmaceutical will be used once it hits the market, researchers are 
often forced to jump to conclusions regarding the effect the 
pharmaceutical will have, and thus the usefulness requirement is 
significantly easier to achieve for chemicals if the inventor proposes 
a pharmaceutical use.    
The interests of inventors are kept in mind with both of these 
standards.  Significant effort is expended in developing a new 
chemical or pharmaceutical drug.  It is only right that protection is 
granted to ensure that this effort is rewarded.  Because, testing on 
humans may pose a risk to the test subject, raising many ethical 
concerns as a result, it is much harder to obtain sufficient data when 
testing pharmaceutical drugs than it is to obtain data on new 
chemicals that can be tested without a live test subject and do not 
raise the same ethical concerns.  It makes sense to loosen the 
usefulness standard in this case in order to encourage the 
development of marketable pharmaceuticals.  Where do genetic 
patents fall in relation?  A gene sequence has a chemical structure of 
its own and could be treated as a new chemical, and many genes are 
eventually put to pharmaceutical use.   
Arguably, standard methods of obtaining gene sequences in the 
lab and accessible databases containing genetic information make it 
even easier to isolate a gene from DNA than to develop a new 
chemical using nothing as a template.  In other words, researchers do 
not have as much effort vested when they apply for a genetic patent.  
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Regardless, many genes being patented receive more lenient 
treatment than other pharmaceuticals.   As seen in Myriad, usefulness 
is achieved based on homology to the function to known genes with 
similar sequencing.  This means that usefulness may be achieved 
prior to the development of a pharmaceutical being derived from the 
gene, and well before the standard applied to pharmaceutical drugs 
that requires that testing then be conducted on the derived 
pharmaceutical that may propose a use.  If less energy is being 
expended on isolating genes, and if pharmaceuticals that are not 
derived from DNA are held to a heightened showing of usefulness, 
then the standard for genetic patents should be that, at a minimum, 
research using the derived pharmaceutical must be presented in order 
to show usefulness.  Or, better yet, using the logic of In re Kirk, gene 
patents should not qualify as a useful invention when their usefulness 
comes from creating something else that has a clear use.  Patents 
would then be reserved only for the products derived from the 
isolated genetic material, and the genetic material itself should be 
rendered ineligible. 
Admittedly, heightening the usefulness standard would have no 
impact on ethical concerns.  It is still up for debate whether DNA, the 
key to unlocking nature, is something that humans should tamper 
with at all.  Also, whether or not genes are discoveries or inventions, 
an issue that may be addressed again in the near future, remains 
unaffected by a heightened usefulness requirement.  It is likely, 
however, that both of these issues are in our rearview and focusing 
on them would be fruitless in trying to change the future of genetic 
patenting.  So, what impact could a heightened usefulness standard 
actually have? 
A heightened usefulness would have no impact on the underlying 
principles of patent law.  Effectively, all a heightened standard would 
do is adjust the timing for when reward is received for the fruits of a 
researcher’s labor.  Researchers still get their reward, but only upon 
the showing of an invention that has proven itself useful.  That is, a 
researcher would only be rewarded once it is shown that he has 
upheld his end of the deal.  This does not eliminate the incentive for 
researchers to invent, and the additional burden in showing actual 
usefulness is not significant enough to deter companies and 
institutions from conducting research.  A heightened usefulness 
standard, in reality, only brings the usefulness requirement into 
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existence.  For, as of now, usefulness is not really required at all for 
genetic patenting. 
Undoubtedly, complaints will arise from corporations because 
some profits will be lost if they are unable to obtain patents prior to 
developing a pharmaceutical from an isolated gene.  This is true.  
Some profits will be lost.  However, those lost profits are the profits 
that come from licensing genetic patents to outside researchers who 
may be able to put the isolated genes to use – the lost profits would 
be those profits that are fueled by the “Big Freeze,” by hindering 
research, and by stunting the growth of innovation.  If the goal of 
patents is to protect innovators, and if an innovation is something 
new, not obvious, and useful, then corporations will not lose any 
money earned from patents that comply with this goal.  If 
corporations can put out a product that is of use to society, then they 
shall receive protection and shall earn the right to profit from the 
fruits of their labor. 
Genetic patents are being granted on a promise that a use will be 
found.  No more promises.  A heightened usefulness standard creates 
an otherwise unopened window of advancement.  For, in the time it 
takes for an individual who isolated a gene to demonstrate the 
usefulness of it, many other uses could simultaneously be found by 
many other scientists.  Research could flourish as licenses would no 
longer be needed in order to use a genetic sequence, and the 
expenditures that would have gone towards a license could now be 
fed back into research and additional innovation.  The incentive to 
invent would remain, but the “Big Freeze” would be no more. 
 
VI. CONCLUSION 
 
 Stemming from the United States Constitution, patents are an 
integral part of American culture, capitalism, and business.  Patents 
protect the innovative, guaranteeing that they will be rewarded for 
the inventions they create.  Patents are supposed to inspire profit and 
growth, and ensure that the public will see the benefit.  On occasion, 
the unfortunate truth is that plenty of profits are made, but society 
does not see the benefit.  Instead, patents necessary to further 
research hinder and delay research – defying the goals of the patent 
system.  Genetic research has led to significant societal contributions 
in agriculture, as well as in the medical field with the development of 
new pharmaceuticals.  More recent research shows great promise.  
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However, sometimes research requires collaborative efforts and 
multiple licenses must be obtained in order to progress.  Maybe that 
is just the price that must be paid to play the game – or maybe the 
patents that are hindering research should be reconsidered. 
Patenting genetic material has raised several issues.  Some have 
contemplated the ethics of tampering with our own genetic material.  
Some have argued that DNA is naturally occurring, and should not 
qualify for patent protection at all.  As it stands, patents to protect 
genetic material are constantly being granted, and we are still in the 
midst of the “Big Freeze.”  Because of readily available genetic 
information and streamlined laboratory techniques, serious 
reconsideration of the nonobvious standard has occurred.  This 
reconsideration may be necessary, and the nonobvious standard may 
be a real issue that should be dealt with – but it is not the only issue. 
The standards for meeting the usefulness requirement are nearly 
nonexistent when dealing with genetic patents.  The requirement is 
met on credit.  A patent applicant need not show that the gene 
sequence is useful, but merely promise that it might be useful with 
further research.  If patent applicants are held to the burden of 
actually producing enough data to show a use, the window of 
opportunity for other researchers to take full advantage of the soon-
to-be-patented gene.  Likely, the only use the gene has is that it will 
be used to produce something else, such as a protein that may be used 
to develop pharmaceuticals.  If this is the case, then a patent should 
be granted on the pharmaceutical, but the gene sequence should 
remain unpatentable until a direct use is shown.  Researchers who 
find the locations of previously undiscovered gene sequences will 
still be incentivized, but the incentive will come from inventing 
something from the genetic material they have replicated.  Businesses 
will oppose this idea.  Profits in licensing will be lost, but the 
integrity of the patent system will remain intact.  Sometimes it is 
necessary to take a step back and ask, “What’s the use?” 
 
